CD274 and neoplasm: Furthermore, evaluation of ctDNA changes by tumor tTMB and PD-L1 status shows findings consistent with other posttreatment measures of efficacy (BOR, PFS, OS; that is, differential outcomes with chemotherapy and pembrolizumab according to key tumor biology).